Cloud Publications
International Journal of Advanced Ayurveda, Yoga, Unani, Siddha and Homeopathy
2026, Volume 15, Issue 1, pp. 960-967
ISSN: 2320–0251

Review

Phyllanthus niruri in the Management of Urolithiasis: A Comprehensive Integrative Review

Rita Kumari, Suman Sinha, Brajesh Kumar, Haresh Kumar Maharaj

Department of Practice of Medicine, R.B.T.S. Govt. Homoeopathic Medical College & Hospital, Muzaffarpur

Correspondence should be addressed Dr. Rita Kumari, PG Scholar, *ritakumariaiapget2023@gmail.com*

Publication Date: 4 August, 2026

Abstract Urolithiasis is among the most frequently encountered urinary disorders in both classical and integrative clinical practice, marked by high recurrence and considerable morbidity. Phyllanthus niruri L. (Euphorbiaceae), known in vernacular usage as "stone-breaker" or Bhumi Amla, occupies a distinct place in homoeopathic materia medica following its drug proving by the Central Council for Research in Homoeopathy (CCRH) and has simultaneously attracted sustained pharmacological interest as an antiurolithiatic botanical. This article reviews the homoeopathic understanding of Phyllanthus niruri derived from proving symptoms and clinical verification, and juxtaposes it against experimental and clinical evidence from contemporary nephrology and urology literature. The aim is to help postgraduate scholars appreciate where symptom-based homoeopathic prescribing and mechanism-based pharmacological research converge, and where important evidentiary gaps remain, so that the remedy may be used with both traditional fidelity and scientific awareness.

Keywords *Phyllanthus niruri; urolithiasis; nephrolithiasis; homoeopathic materia medica; drug proving; integrative nephrology*

Introduction

Renal and ureteric calculi affect a substantial proportion of the adult population worldwide, and the recurrence rate after a first stone episode exceeds fifty percent within a decade. Conventional management ranges from dietary modification and medical expulsive therapy to extracorporeal shock wave lithotripsy (ESWL) and endourological intervention, yet the search for safe, low-cost adjuncts that reduce recurrence and ease stone passage continues. Phyllanthus niruri has long occupied this space in folk and traditional systems of medicine, most notably in Brazilian ethnobotanical practice, where it is popularly called "quebra-pedra" (stone-breaker), and in Indian Ayurvedic and Siddha traditions as Bhumi Amla.

In homoeopathy, the same plant was subjected to a formal drug proving conducted by the CCRH at its Drug Proving Research Units in Ghaziabad and Kolkata during 1994-95, with an independent proving subsequently published by Dr George Mathew. The resulting materia medica, read alongside decades of pharmacological research on the plant, provides postgraduate scholars an unusually well-documented opportunity to compare a symptom-based homoeopathic remedy picture

with a mechanism-based scientific literature on the very same botanical source — a comparison this article undertakes for the specific indication of urolithiasis.

The Homoeopathic Materia Medica of Phyllanthus niruri

Botanical Source and Preparation: Phyllanthus niruri Linn. (synonyms include Phyllanthus amarus and Diasperus niruri, though some authors regard these as distinct varieties) is a small annual herb of the family Euphorbiaceae, distributed across tropical and subtropical regions including India, Brazil and Southeast Asia. The homoeopathic mother tincture is prepared from the whole fresh plant. Classical Indian ethnobotanical literature, notably Nadkarni's Indian Materia Medica, records the plant as de-obstruent, diuretic, astringent and cooling, historically used in jaundice, dropsy and genitourinary affections — a description that anticipates much of its later homoeopathic and pharmacological use.

Drug Proving and Clinical Verification: The CCRH proving, published in "New Drugs Proved by CCRH" (2008), together with Mathew's independent proving, describes a remedy with a marked affinity for the hepatic and urinary systems. Provers reported renal colic-type pain radiating toward the groin, burning during micturition, scanty and high-coloured urine, and a distinctive sensation of "sand" passing with the urine — symptoms that closely mirror the clinical picture of urolithiasis with or without associated crystalluria. A parallel affinity for the liver (right hypochondriac pain, distension after food) is also prominent, consistent with the plant's traditional hepatoprotective reputation. On the mental plane, provers noted irritability over trifles and an anxious, somewhat indifferent mood during acute illness, features useful in individualising the remedy in practice.

Table 1. Comparative overview of the homoeopathic and pharmacological perspectives on Phyllanthus niruri in urolithiasis

Parameter	Homoeopathic Perspective	Contemporary Pharmacological Perspective
Basis of use	Symptom-similarity derived from drug proving (CCRH, 1994-95) and clinical verification	Bioactive constituents acting on crystallisation and smooth muscle
Preparation	Mother tincture (Q) from whole fresh plant; potencies 6C-200C	Aqueous/hydro-alcoholic extract, standardised capsules (e.g., 450 mg tid)
Reported renal action	"Renal colic, sand-like deposits, burning micturition, calculi with backache"	Reduced CaOx crystal growth/aggregation, mild diuresis, possible ureteral relaxation
Concomitant organ affinity	Marked hepatic and gastrointestinal symptoms alongside urinary complaints	Hepatoprotective, anti-inflammatory and antioxidant activity independently documented
Level of evidence	Proving data, clinical verification, repertorial records	Experimental (animal/cell) studies; a small number of randomised trials

Table 2. Representative symptoms from the CCRH proving and clinical verification of Phyllanthus niruri

Sphere	Representative Proving / Clinical Symptoms
Urinary	Pain in kidney region radiating to groin; burning during micturition; scanty, high-coloured urine; sensation of sand passing with urine; renal colic with restlessness
Hepatic / Abdominal	Pain in right hypochondrium, hepatomegaly, jaundice, distension after food, aversion to fatty food
Mind	Irritability on trifles, anxiety with depression, indifference/no desire to work during illness
Generals	Weakness, better for rest, thirst variable, aggravation from rich/fatty food

Clinical Use in Homoeopathic Practice: In clinical homoeopathic practice, Phyllanthus niruri is most often employed in mother tincture or low potency for renal colic, recurrent calculi and calculous dyspepsia with hepatic involvement, and it also finds mention for viral hepatitis and other bacterial or viral infections given the plant's broader traditional reputation as an antiviral and hepatoprotective agent. Prescription typically follows the totality-of-symptoms approach characteristic of homoeopathy rather than diagnosis alone, with the remedy chosen when the urinary picture is accompanied by the concomitant hepatic and mental features described in its materia medica.

Contemporary Pharmacological and Clinical Evidence

Phytochemistry: More than fifty compounds have been isolated from Phyllanthus niruri, including lignans (phyllanthin, hypophyllanthin), alkaloids, flavonoids (quercetin, rutin), triterpenes (beta-amylin, beta-sitosterol), tannins (geraniin) and phenolic acids such as ellagic and caffeic acid. Several of these constituents have been individually linked to antiurolithiatic activity, most notably the triterpene fraction, which has been shown to protect against calcium oxalate crystal-induced peroxidative injury, and ellagic acid, more recently identified through network pharmacology as a key active ingredient protecting renal tubular cells from calcium oxalate-induced injury via lipid-metabolism-related targets.

Proposed Mechanisms in Stone Disease: Experimental work from the Federal University of São Paulo group demonstrated that Phyllanthus niruri interferes with several sequential steps of stone formation: it reduces calcium oxalate crystal aggregation, alters crystal structure and composition, and modifies the interaction between crystals and renal tubular cells, thereby reducing subsequent crystal endocytosis. Additional proposed mechanisms include a mild ureteral or urethral relaxant effect — plausibly assisting the passage of small calculi or residual fragments after lithotripsy — and modulation of urinary excretion of stone-forming constituents such as calcium, oxalate and uric acid, particularly in patients with underlying metabolic abnormalities such as hypercalciuria or hyperoxaluria.

Figure 1. Proposed convergence between the homoeopathic and pharmacological understanding of Phyllanthus niruri in urolithiasis



Homoeopathic materia medica (symptom-based selection) and pharmacological research (mechanism-based evidence) converge on a common clinical observation, though neither fully explains the other.

Clinical Trial Evidence: Clinical evidence, while encouraging, remains limited in volume and consistency. Nishiura and colleagues randomised 69 calcium stone-forming patients to Phyllanthus niruri or placebo for three months; while overall stone voiding and pain relief did not differ significantly between groups, a significant reduction in urinary calcium excretion was observed specifically among hypercalciuric patients. In a larger prospective study, Micali and colleagues followed 150 patients after extracorporeal shock wave lithotripsy and found no significant difference in stone clearance between those given a standardised P. niruri extract (Uriston) and controls, though no adverse renal, cardiovascular or neurological effects were noted in either group. More recently, Pucci and colleagues reported that a twelve-week course of P. niruri infusion increased urinary magnesium and potassium and reduced urinary oxalate and uric acid selectively in patients with hyperoxaluria or hyperuricosuria, again pointing to a metabolic-subgroup-dependent benefit rather than a uniform effect.

Figure 2. Sample sizes and directionality of outcome across key studies of Phyllanthus niruri in urolithiasis



Table 3. Summary of principal experimental and clinical studies

Study	Design / n	Key Finding
Freitas et al. 2002 (BJU Int)	Rat CaOx model, n=22 treated	Inhibited matrix calculus growth and reduced satellite stone number; effect linked to altered glycosaminoglycan handling
Nishiura et al. 2004 (Urol Res)	RCT vs placebo, n=69 stone-formers	No overall change in stone voiding/pain, but significant fall in urinary calcium in the hypercalciuric subgroup
Micali et al. 2006 (J Urol)	Prospective, post-ESWL, n=150	No significant difference in stone-free rate between P. niruri and control groups after lithotripsy
Pucci et al. 2018 (Int Braz J Urol)	Prospective crossover, n=56	Increased urinary magnesium/potassium; reduced oxalate and uric acid in hyperoxaluric/hyperuricosuric patients
Li et al. 2022 (Front Pharmacol)	Network pharmacology + HK-2 cell/animal model	Ellagic acid identified as key active constituent protecting tubular cells from CaOx-induced injury via lipid-metabolism targets

Bridging Homoeopathic Materia Medica and Contemporary Evidence

This literature suggests three points of convergence and two persistent gaps. First, both traditions independently arrived at the same organ affinity: homoeopathic proving symptoms centre on renal colic, sandy urinary deposits and concomitant hepatic disturbance, while pharmacological studies independently confirm renal tubular and hepatic actions of the same plant — an instance where the doctrine of proving and modern organ-specific pharmacology point in the same direction without either having been designed with the other in mind. Second, the homoeopathic emphasis on individualisation (the hypercalciuric or metabolically deranged patient responding preferentially) finds an interesting, if coincidental, parallel in the clinical trials, where benefit was consistently confined to metabolic subgroups (hypercalciuria, hyperoxaluria, hyperuricosuria) rather than appearing uniformly across all stone formers. This subgroup-dependence is arguably the single most important bridge between the two literatures: it lends indirect support to the homoeopathic principle that remedy response is conditioned by the totality of the individual's metabolic and constitutional state rather than by diagnosis alone.

Third, both bodies of evidence agree that the remedy is well tolerated, with no significant adverse renal, cardiovascular or toxic effects reported in either homoeopathic clinical use or in the pharmacological trials reviewed here, which supports its cautious use as a low-risk adjunct.

The gaps, however, are equally instructive. Homoeopathic potencies (typically 6C and above) contain the plant material at ultra-molecular dilution, whereas nearly all pharmacological studies used mother-tincture-equivalent or crude extract doses; direct extrapolation of pharmacological mechanism to potentised homoeopathic prescribing therefore remains conjectural rather than established. Equally, no controlled trial to date has tested a homoeopathically potentised preparation of Phyllanthus niruri against placebo in urolithiasis using individualised, symptom-based selection — the studies cited here all used standardised crude extract regardless of the patient's total symptom picture. Bridging these traditions rigorously would require homoeopathic pathogenetic trials conducted to modern methodological standards and, ideally, pragmatic clinical trials of individualised homoeopathic prescribing (not merely mother-tincture administration) in defined urolithiasis populations.

Limitations of Current Evidence

- Most pharmacological trials are small, single-centre, and of short duration (typically three months), limiting conclusions about long-term stone recurrence.
- Outcome heterogeneity: studies report a mixture of biochemical (urinary calcium, oxalate), radiological (stone size/number) and clinical (pain, expulsion) endpoints, complicating direct comparison.
- None of the identified clinical trials employed a homoeopathically potentised preparation or individualised prescribing methodology.
- Publication is concentrated in a small number of research groups (notably the São Paulo nephrology unit), so independent replication remains limited.
- Homoeopathic proving data, while systematically recorded by CCRH, has not been subjected to blinded clinical verification specifically in urolithiasis.

Future Scope

- Conduct large-scale, multicentre randomized controlled trials to evaluate the efficacy of *Phyllanthus niruri* in urolithiasis.

- Investigate the effectiveness of individualized homoeopathic prescribing using potentized *Phyllanthus niruri*.
- Compare the clinical outcomes of mother tincture and different homoeopathic potencies.
- Assess long-term efficacy in preventing stone recurrence through extended follow-up studies.
- Explore the role of *Phyllanthus niruri* as an adjunct to conventional therapies such as ESWL and medical expulsive therapy.
- Perform biomarker-based studies to evaluate its effects on urinary biochemical parameters and renal function.
- Validate the homoeopathic proving symptoms through modern pathogenetic and clinical verification studies.
- Conduct subgroup analyses in patients with hypercalciuria, hyperoxaluria, and recurrent calcium oxalate stones.
- Investigate the molecular mechanisms of action using pharmacological and systems biology approaches.
- Promote interdisciplinary research integrating homoeopathy, pharmacology, and clinical nephrology to strengthen the evidence base.

Conclusion

Phyllanthus niruri exemplifies a botanical remedy in which homoeopathic materia medica and contemporary pharmacology, though developed through entirely different epistemologies, describe a strikingly congruent clinical picture in urolithiasis: renal colic, sandy urinary deposits, hepatic concomitance, and a therapeutic response that appears most pronounced in metabolically predisposed individuals. For the postgraduate scholar, the remedy offers a useful case study in integrative reasoning — one where symptom-similarity and mechanistic plausibility reinforce rather than contradict each other, even as the evidence base for potentised, individualised homoeopathic prescribing in this indication remains to be built through dedicated clinical research.

References

[1] Central Council for Research in Homoeopathy. New Drugs Proved by CCRH. New Delhi: CCRH; 2008.

[2] Mathew G. Phyllanthus niruri or Bhuiamla: Proving and Clinical Verification. Homeobook.com; reproduced by Dr Willmar Schwabe India, Schwabeindia.com Doctor News.

[3] Nadkarni KM. Dr K. M. Nadkarni's Indian Materia Medica. Vol. 1. 3rd ed. Revised and enlarged by Nadkarni AK. Bombay: Popular Prakashan; p. 948.

[4] Hpathy.com. Phyllanthus Niruri or Stonebreaker — Mother Tincture Homeopathy Remedy. Materia Medica section, Hpathy.com; 2016.

[5] Boim MA, Heilberg IP, Schor N. Phyllanthus niruri as a promising alternative treatment for nephrolithiasis. Int Braz J Urol. 2010;36(6):657-64.

[6] Freitas AM, Schor N, Boim MA. The effect of Phyllanthus niruri on urinary inhibitors of calcium oxalate crystallization and other factors associated with renal stone formation. BJU Int. 2002;89(9):829-34.

[7] Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N. Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res. 2004;32(5):362-6.

[8] Micali S, Sighinolfi MC, Celia A, De Stefani S, Grande M, Cicero AF, et al. Can Phyllanthus niruri affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. J Urol. 2006;176(3):1020-2.

[9] Pucci ND, Marchini GS, Mazzucchi E, Reis ST, Srougi M, Evazian D, Nahas WC. Effect of Phyllanthus niruri on metabolic parameters of patients with kidney stone: a perspective for disease prevention. Int Braz J Urol. 2018;44(4):758-64.

[10] Malini MM, Lenin M, Varalakshmi P. Protective effect of triterpenes on calcium oxalate crystal-induced peroxidative changes in experimental urolithiasis. Pharmacol Res. 2000;41(4):413-8.

[11] Bagalkotkar G, Sagineedu SR, Saad MS, Stanslas J. Phytochemicals from Phyllanthus niruri Linn. and their pharmacological properties: a review. J Pharm Pharmacol. 2006;58(12):1559-70.

[12] Lee NYS, Khoo WKS, Adnan MA, Mahalingam TP, Fernandez AR, Jeevaratnam K. The pharmacological potential of Phyllanthus niruri. J Pharm Pharmacol. 2016;68(8):953-69.

[13] Li MT, Liu LL, Zhou Q, Huang LX, Shi YX, Hou JB, Lu HT, Yu B, Chen W, Guo ZY. Phyllanthus niruri L. exerts protective effects against the calcium oxalate-induced renal injury via ellagic acid. Front Pharmacol. 2022;13:891788.

[14] Kieley S, Dwivedi R, Monga M. Ayurvedic medicine and renal calculi. J Endourol. 2008;22(8):1613-6.

[15] Similia India. Phyllanthus niruri Mother Tincture — Product Monograph. Similiaindia.com.